

Extraordinary Report

March 29 , 2019

(TRANSLATION)

Note for readers of this English translation

On March 29, 2019, Chugai Pharmaceutical Co., LTD. (the “Company”) filed its Japanese-language Extraordinary Report (Rinji Houkokusho) (the “Report”) with the Director-General of the Kanto Financial Bureau in Japan in connection with the Company's shareholders' voting results for proposals acted upon at the 108th Annual General Meeting of Shareholders held on March 28, 2019 pursuant to the Financial Instruments and Exchange Act of Japan. This document is an English translation of the Report.

1. Reason for submitting the Extraordinary Report

Given that resolutions were made for the proposals at the 108th Annual General Meeting of Shareholders (the “Meeting”) held on March 28, 2019, Chugai Pharmaceutical Co., Ltd (the “Company”) submits this Extraordinary Report under the provisions of Article 24-5, Paragraph 4, of the Financial Instruments and Exchange Act of Japan and Article 19, Paragraph 2, Item 9-2, of the Cabinet Office Ordinance on Disclosure of Corporate Information, etc.

2. Contents of the Extraordinary Report

(1) Date when the Meeting was held: March 28, 2019

(2) Matters for resolution

First Proposal Appropriation of Surplus

Year-end dividend

JPY 55 per share of common stock of the Company

Second Proposal Election of Five (5) Directors

Masayuki Oku, Yoichiro Ichimaru, Christoph Franz, William N. Anderson, and James H. Sabry were elected as directors of the Company.

Third Proposal Election of Two (2) Audit & Supervisory Board Members

Atsushi Sato and Yuko Maeda were elected as Audit & Supervisory Board Members of the Company.

(3) Number of voting rights concerning the indication of "for", "against" or "abstention"

for each proposal; and Requirements for approving the proposals: Results of resolutions

Proposal	For	Against	Abstention	Ratio of favorable votes	Results
First Proposal	5,168,022	221	33	99.99%	Approved
Second Proposal					
Masayuki Oku	5,089,014	78,841	413	98.46%	Approved
Yoichiro Ichimaru	5,136,356	31,878	33	99.38%	Approved
Christoph Franz	5,117,667	50,573	33	99.02%	Approved
William N. Anderson	5,129,351	38,889	33	99.24%	Approved
James H. Sabry	5,129,350	38,890	33	99.24%	Approved
Third Proposal					
Atsushi Sato	5,043,274	124,957	33	97.58%	Approved
Yuko Maeda	5,167,252	991	33	99.98%	Approved

Notes: Requirements for the approval of each proposal are as follows:

- 1) The resolution for the First Proposal must be adopted by a majority of the votes of the shareholders present at the Meeting, who are entitled to exercise voting rights.
 - 2) The resolution for the Second and Third Proposals must be adopted by a majority of the votes of the shareholders present at the Meeting where the number of the voting rights of the shareholders present, amounts to one-third (1/3) or more.
- (4) Reason why a portion of the voting rights held by the shareholders present at the Meeting held on March 28, 2019 was not added to the number of voting rights

Because in terms of Japanese Companies Act, the required majority approval for each proposal was met by the votes exercised prior to the Meeting held on March 28, 2019, as well as the votes exercised by a portion of shareholders present and confirmed by the Company at the Meeting held on March 28, 2019; and the voting rights of the shareholders present at the Meeting held on March 28, 2019, untraceable with the final decision of "for", "against" or "abstention" as to each proposal were not tallied.